Categories: Health

IPSEN – Buy-back programme – Art 5 of MAR – Week 36 – 2025

Aggregated presentation by day and by market

Statement of transactions in own shares from 1st September to 5th September 2025
             
Name of the issue Identity code of the issuer
(Legal Entity Identifier) 		Day of the transaction Identity code of the financial instrument Total daily volume (in number of shares) Daily weighted average purchase price of the shares Market         (MIC Code)
  IPSEN 549300M6SGDPB4Z94P11 01/09/2025 FR0010259150    632 116,87753 AQEU  
  IPSEN 549300M6SGDPB4Z94P11 01/09/2025 FR0010259150   1 200 116,94167 CCXE  
  IPSEN 549300M6SGDPB4Z94P11 01/09/2025 FR0010259150    200 116,90 TQEX  
  IPSEN 549300M6SGDPB4Z94P11 01/09/2025 FR0010259150   2 606 117,18388 XPAR  
  IPSEN 549300M6SGDPB4Z94P11 02/09/2025 FR0010259150    300 116,20 AQEU  
  IPSEN 549300M6SGDPB4Z94P11 02/09/2025 FR0010259150    500 116,20 CCXE  
  IPSEN 549300M6SGDPB4Z94P11 02/09/2025 FR0010259150    200 116,286 TQEX  
  IPSEN 549300M6SGDPB4Z94P11 02/09/2025 FR0010259150   3 600 116,41622 XPAR  
  IPSEN 549300M6SGDPB4Z94P11 03/09/2025 FR0010259150    300 116,70 AQEU  
  IPSEN 549300M6SGDPB4Z94P11 03/09/2025 FR0010259150    600 116,68333 CCXE  
  IPSEN 549300M6SGDPB4Z94P11 03/09/2025 FR0010259150    300 116,50967 TQEX  
  IPSEN 549300M6SGDPB4Z94P11 03/09/2025 FR0010259150   3 400 116,95335 XPAR  
  IPSEN 549300M6SGDPB4Z94P11 04/09/2025 FR0010259150   1 200 120,00 CCXE  
  IPSEN 549300M6SGDPB4Z94P11 04/09/2025 FR0010259150   3 400 119,88147 XPAR  
  IPSEN 549300M6SGDPB4Z94P11 05/09/2025 FR0010259150    300 120,00 € AQEU  
  IPSEN 549300M6SGDPB4Z94P11 05/09/2025 FR0010259150    600 120,05 CCXE  
  IPSEN 549300M6SGDPB4Z94P11 05/09/2025 FR0010259150    300 120,00 TQEX  
  IPSEN 549300M6SGDPB4Z94P11 05/09/2025 FR0010259150   3 400 119,80815 XPAR  
            23 038 118,01642    
                 
GlobeNews Wire

Share
Published by
GlobeNews Wire
Tags: 2025Adventureartbuy-backFR0010259150ipsenmar”newsParis:IPNPressReleaseprogrammeRegulated_Infoweek
5 months ago

Recent Posts

Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

February 06, 2026 16:01 ET  | Source: Ocular Therapeutix, Inc. BEDFORD, Mass., Feb. 06, 2026…

10 hours ago

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 06, 2026 16:01 ET  | Source: NewAmsterdam Pharma N.V. NAARDEN, The Netherlands and MIAMI,…

10 hours ago

Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery

New facility will enable end‑to‑end discovery across key disease areas and technology platforms, joining existing…

10 hours ago

The Ministry of Finance and the International Monetary Fund to launch tomorrow the second edition of the AlUla Conference for Emerging Market Economies

AlUla, Saudi Arabia, Feb. 7, 2026 /PRNewswire/ -- The second edition of the AlUla Conference…

10 hours ago

Roches fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS)

Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint…

10 hours ago

Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement

February 06, 2026 17:17 ET  | Source: Lexicon Pharmaceuticals, Inc. THE WOODLANDS, Texas, Feb. 06,…

10 hours ago